

The SNOMED CT Encoded Unified Test List (UTL) Editorial Principles v1.2

Information and technology
for better health and care

Revision History

Version	Date	Summary of Changes
0.5	08/11/2019	First draft for review
1.0	25/11/2020	V0.5 formally approved by the PSGB as a live document amended according to need
1.1	26/01/2021	Updates to align with UTL v0.6.0
1.2	17/01/2021	Updates to align with UTL v0.7.0 – Qualitative interpretation UTL pattern for beta review

Contents

1. Introduction	4
1.1. Antecedent laboratory code sets (Read/PBCL)	4
1.2. International Reference Standards	4
1.3. Ownership	5
2. Scope and Structure	5
2.1. Scoping the Coverage of the Principles	5
2.2. The Structure of SNOMED Descriptions	5
2.3. Units of Measurement (UoMs)	7
2.4. Test Preconditions	7
2.5. Clinical Domain and Sub-domain Coverage	7
3. Content Patterns	8
3.1. 'Amounts and Counts' - The Concept of 'Quantity' In Laboratory Results Categorisation	8
3.2. Other Result Property Types	9
3.3. Content Patterns - Worked Examples	10
3.4. Other Worked examples	15
3.5. Further Definition Of Concepts By Assay/Technique/Method Used	17
3.6. Relative To	17
4. Molecular Biology - Nucleic Acid Amplification	18
5. Batteries/Profiles/Panels, Screens and Dynamic Function Tests etc.	18
6. Generating Regular SNOMED-Conformant Descriptions From User Requirements	19
6.1 Thing/Property/System Triad + Technique + Relative To	19
6.2 Summary of Heuristic Term Formations	19
7. Classifying Lab Medicine Observables IN SNOMED	19
Appendix 1: Links to Online Resources	21
Appendix 2: Core Attributes and Values Sets	22
Appendix 3: Domain-Specific Abbreviation Conventions	24

Editorial Principles for the SNOMED CT Encoded Unified Test List (UTL) for the UTL v0.5

1. Introduction

This document describes the format for clinical terming of clinical laboratory results in the UK based on specific attributes and values that have equivalence across ontologies. It supports a templating approach to content development. It does this in a way that conforms with SNOMED CT editorial principles and maximises interoperability. It will remain a dynamic document, keeping up with the latest developments in international editorial thinking. The guide is framed by the SNOMED CT concept model for observable entities set out by SNOMED International. Guidance for laboratory observables may vary from that for other types of observable such as functional observables.

The guide pertains only to content within the UK Edition of SNOMED CT and is dependent on use and licensing requirements described in the documentation that accompanies releases of that Edition. The formal name 'SNOMED CT®' is abbreviated to 'SNOMED' throughout for readability; laboratory is often shortened to 'lab'.

The guide seeks to represent in SNOMED in a faithful, logical way the laboratory medicine knowledge that is defined by subject domain experts but it is not intended as a specialist guide to laboratory medicine as such.

Feedback on the product, individual representations and on these draft Editorial Principles is welcomed via email at: pathologyanddiagnostics@nhs.net

1.1. Antecedent laboratory code sets (Read/PBCL)

It is impossible to set out editorial guidance for a developing product without noting the long-standing and continuing daily volume flows of lab results reporting to General Practices in the UK using the Pathology Bounded Code List (PBCL) and EDIFACT messaging. This highly successful and internationally noteworthy product is however based on ageing Read V2 and Read V3 (CTV3) coding that has now been superseded by SNOMED. The UTL further develops the 'reportables' aspect of the National Laboratory Medicine Catalogue (NLMC) and is the projected successor to the PBCL reportables alongside the anticipated replacement of the carrier EDIFACT messaging standard by HL7 FHIR profiles. The UTL acknowledges the considerable intellectual work done in the interim National Laboratory Medicine Catalogue (NLMC) to regularise content format and the pathology 'requestable/reportable' (requests/results) model. That work informs the current iteration of laboratory medicine report standards.

1.2. International Reference Standards

SNOMED CT is the recognised NHS standard for clinical data entry in electronic health and care records. The NHS decided in 2017/18 to pursue the development of a lab results PBCL replacement solution within SNOMED CT while recognising the other reference lists that exist with the potential to be mapped to it in the future.

The Nomenclature, Properties and Units (NPU) test lists derived from IUPAC standards and in use in other European countries provides a useful cross-reference, while more general IUPAC metrologic principles are also used to inform the product.

1.3. Ownership

This draft editorial guidance has been developed by the National Pathology and Diagnostics at NHS Digital. National Pathology and Diagnostics is part of IReS (UK Information Representation Services).

The governance of the product will change over time but as a draft product in development it is managed by the National Pathology and Diagnostics team. The guidance, in defining a SNOMED product, supplements or extends (without contradicting) the Editorial Guidelines published for the bi-annual UK Edition of SNOMED CT (which in turn supplement those published by SNOMED International). The UK SNOMED CT Editorial Principles are managed by the SNOMED CT Edition (Editorial) Committee.

2. Scope and Structure

2.1. Scoping the Coverage of the Principles

If the value/result/answer to a laboratory test and observation is categorical or numeric, that answer should be represented in a report artefact by a SNOMED observable entity concept with an attached categorical or numeric value along with units of measurement, reference ranges, test preconditions, alerts, patient and sample identifier etc.

It is proposed for this set of editorial principles that the following draft framework is used to determine scope of SNOMED coding and modelling. This may change over time.

A single lab test with a single result will have the same SNOMED coded observable entity concept for its request and result answer (or a more specifically defined one e.g. by method).

A panel/profile/battery, screen or dynamic function test request will use a SNOMED procedure code and then multiple result SNOMED coded observable entity concept for each result in the panel. Alternatively, a narrative or free text report, possibly including SNOMED clinical findings codes may be sent as a single result of the test but that is out of scope for these principles defining observable entities as lab test result components.

As presently set out, the guidance covers single test results. A separate section or separate document will need to be worked up for request codes in SNOMED i.e. for panels/profiles/batteries, screens or dynamic function tests (DFTs).

2.2. The Structure of SNOMED Descriptions

The guidance describes the detail of standardised term/description forms for Fully Specified Names (FSN), Preferred Terms (PT) and synonymous terms. The aim is to have terms from which the related model attribute/value pairs can be deduced, such that is possible to both build terms from SNOMED code expressions and to build the expressions from the terms in a consistent and machine and human readable form. The terms should conform to the concept model and thereby they will conform to the attribute and qualifier value constraints of the model.

The triad of **Property-OF-Thing-IN-Specimen** with the complementing addition of **Method** form the core of proposed UK modelling at present. These are a subset of the full range of possible attributes that can be defined. Further testing is needed of utility, of auto-classification outcomes and of alignment with planned SNOMED International observables model expansion; other attributes may be introduced where appropriate (for example, 'Relative To' for ratios of one substance to another). The Property/Thing/Specimen triad relate to SNOMED mostly as follows:

Thing (substance, entity or process):	246093002 Component (attribute)
Property:	370130000 Property (attribute)
Specimen:	704319004 Inheres in (attribute)
<i>Technique (or method or assay used):</i>	<i>246501002 Technique (attribute)</i>

Example:

<i>Sodium</i>	<i>molar concentration</i>	<i>[IN] serum</i>
---------------	----------------------------	-------------------

Property: molar concentration

Component (thing/substance): sodium

Inheres in (specimen): serum

In SNOMED the focus of the concept is the property being measured. Hence the FSN word ordering of 'Property', 'Component', 'Inheres In'. However, laboratory specialists would usually describe the thing being measured first when listing tests and this might be expected catalogue behaviour. This latter form is reflected in the Preferred Term that users normally see in systems.

Note that this core set of parts of the term does not preclude the defining or inheritance of other permitted attribute/value pairs in the observables model as it develops. While 'Fully Defined' content within the model is the long term aim it is anticipated that significant volumes of 'Primitive' (i.e. not fully defined) concepts will remain for some time yet.

2.3. Units of Measurement (UoMs)

The general property types that determine (and indeed validate in use) the range of allowed units of measurement are a part of the terming and modelling project for the UTL. **The specific UoM assigned to each result is not included in the description in the UTL member concept.** UoMs are applied in the FHIR result message in a separate field alongside the actual result text and with the reference range and alerts where applicable. The range of valid UoMs are determined from the Property Type attribute. Reference ranges are also not part of the SNOMED model described.

2.4. Test Preconditions

Fasting, random, timed specimens etc.

While there is clearly a need to capture such information, *where* it is captured is yet to be decided. The important point in this is that the essential nature of the test and its result are no different in these further qualified terms. A 'serum glucose' is exactly the same as a 'fasting serum glucose'. Until the mechanism for displaying and retaining this information is determined no items of this form have been included. However, it remains possible that the solution is within SNOMED. For example, the 'fasting' information could be assigned to the sample as a 'serum sample taken from fasted patient'.

2.5. Clinical Domain and Sub-domain Coverage

This guidance currently mainly covers the broad domain of 'blood sciences' (blood but also other body fluids), including:

- Clinical chemical pathology/biochemistry
- Endocrinology
- Haematology
- Immunology
- Some areas of microbiology/virology (e.g. some antibody and antigen reporting).

Domains for subsequent stages of work are:

- Andrology
- Transfusion
- Nucleic acid amplification tests for organisms
- Molecular biology for genetic mutations/Genomics

Some of the above categories may only have minimal content to start with but are expected to expand rapidly over time as UTL development continues.

3. Content Patterns

3.1. 'Amounts and Counts' - The Concept of 'Quantity' In Laboratory Results Categorisation

In ontology, 'quantity' is a basic class of fundamental 'things' along with quality, substance, change and relation. Quantity is further divided by multitude and magnitude.

- Magnitude covers that which is continuous and divisible only into smaller divisibles (such as mass and energy). Such measurements of quantity can be fundamental direct measurements or relational combinations built from these.
- Multitude includes (among other collectives) the notion of number (of indivisible entities - such as cells or organisms).

From this, ontologically or metrologically, but then also by empirical confirmation from laboratory results lists in use, test result observables can be categorised (in common across systematic representational standards) as either scalar magnitudes or multitudes and overwhelmingly of the types (or of variations of the types):

Molar/mass concentration (moles/volume and mass/volume)

or

Entity count (number/volume)

...where 'substance' and 'entity' are fundamental things and 'mass/volume or number/volume' are fundamental properties of things. Most of these thing/property pairs can be further specified in the laboratory by the *in vitro* environment in which they are measured, more specifically a specimen/sample. These three attributes form the core heuristic triad that go towards defining laboratory observables in SNOMED and, not surprisingly given the fundamentals, in other reference terminologies. This triad can then be further defined through the SNOMED concept model by several other attributes described below but the triad remains the core of the representation.

In order to support the development of very new, untested UTL content against an emerging standard, a framework is needed and the pragmatic model being used might be best characterised as one of 'epistemic iteration' (avoiding the 'nomic measurement problem' between metrologic theory and empirical validation of theory, i.e. 'which of these prevails or comes first'). Here, empirical practice iteratively informs theory which informs empirical practice with due regard to international scientific nomenclature and conventions and in continuous communication with clinical domain leads for validation. It permits the operational activities that build a new product.

3.2. Other Result Property Types

Substance/mass concentration and entity count are not the only types of results, but just the main and most common categories. Below are some other common types of results (but some are refinements of those described above): [note: this is an evolving characterisation]

Amount	<p>Direct scalar measurement e.g. volume, weight, viscosity, osmolality pH etc</p> <p>OR</p> <p>Concentration: an amount in a fluid volume</p> <p>OR</p> <p>Semi-quantitative amount e.g. 'nitrites +++'</p>
Count	'Absolute' count of entities: a count (commonly of blood cells) in a volume
Fraction or Relative Amount or Count	<p>Concentration Ratio: one (UoM) concentration to another, often to creatinine</p> <p>OR</p> <p>Percent: a fraction, saturation or count relative to a superset count then expressed as a relative percentage of it.</p> <p>OR</p> <p>'Pure' ratio (dimensionless, 'UoM-less')</p> <p>OR</p> <p>Index: has a similar basis as percent as an expression of a quantitation e.g. Antibody index (relative to 1.0)</p>
Qualitative Presence/Absence/equivocal/unknown	Presence: derived from quantitation where reported as positive if above a cut-off or threshold value, used to report on detection tests
Time	Relative/elapsed time (from zero not clock time) - mainly clotting times
Rate	Quantity against time
Output/Excretion	Quantity specifically in 24 hours and often in urine (note: may be modelled as a simple mass/molar defined in SNOMED 'Process duration (attribute)': '/day')
Titre	Becoming less frequently used
Activity	Catalytic (enzyme) and other substance activity
Calculation	Result arrived at by formula from quantitations e.g. eGFR, AKI warning stage, clearance

Type, subtype, group, class, grade, phenotype, identity etc.	Classification/category
Narrative text	Text report on an examination, study, dynamic function test, composite test interpretation, conclusion etc

The two common subdivisions above, with smaller numbers of the patterns in the above table, comprise much of UK laboratory result content analysed so far for UTL inclusion.

From the categories above, inputs to the UTL can be parsed to support the standardisation of terminology and modelling. However, some test names/results are condensed forms, eponymous or termed from historic usage and, from which, inferences on modelling cannot be easily drawn directly. As usage over time means these are well established and defined, no attempt is being made at this stage to expand them in a long form encyclopaedic manner, for example:

APTT - Activated Partial Thromboplastin Time
 INR – International Normalised Ratio
 Coombes Test

However some of these may be defined more fully on a case basis. Semantic constructions not fitting with the above patterns and specifically, those not bearing a direct single result, are dealt with in later sections. These are usually terms standing for evaluation procedure such as screening test results, study conclusions, function test results and profiles/batteries/panels.

3.3. Content Patterns - Worked Examples

3.3.1 Substance (molar) concentration and mass concentration

The following pattern can be repeated for any component reported with a mass or molar concentration unit of measurement.

Property Attribute | Value Pair

370130000 | Property (attribute) | 118539007 | Mass concentration (property) (qualifier value)
 370130000 | Property (attribute) | 118556004 | Substance concentration (property) (qualifier value)

Example: Oxalate

FSN: Mass concentration of oxalate in plasma
 UK PT: Oxalate mass concentration in plasma

FSN: Mass concentration of oxalate in serum

PT: Oxalate mass concentration in serum

FSN: Substance concentration of oxalate in plasma

UK PT: Oxalate molar concentration in plasma

FSN: Substance concentration of oxalate in serum

UK PT: Oxalate molar concentration in serum

Notes

Mass concentration denotes mass/volume UoMs such as 'mg/L'

Substance concentration denotes moles/volume UoMs such as 'mmol/L' and is conventionally written as molar concentration by UK labs.

The word 'specimen' is usually redundant and left out

The FSN currently uses the current international terming order convention '*property of thing in specimen*' although this can sometimes produce incongruous terms.

The PT places the thing first for ordering/indexation based on this being the key element from a clinical utility perspective.

'Molar concentration' is more familiar usage to UK labs while 'substance concentration' is used more internationally.

3.3.1.1 Quantitations reported both as concentrations and as interpreted qualitative results based on cut-off/threshold value

Either or both a quantitation concept and a 'presence' concept are provided unless the quantitative result is not reported.

Example: Adalimumab antibodies (draft for consultation)

Quantitation:

FSN: Mass concentration of adalimumab antibody in serum

PT: Adalimumab antibody mass concentration in serum

Qualitative result based on quantitative cut-off value:

FSN: Presence of adalimumab antibody in serum

PT: Adalimumab antibody presence in serum

Alternatively, a titre or antibody index cut off could be used. Users are free to use any conventional qualitative forms (positive/negative, detected/not detected) but the detection report describes where the presence or otherwise is asserted based on a cut-off value or threshold.

Please note (presence pattern), the sample of microorganism nucleic acid SNOMED CT reporting concepts by presence of RNA/DNA in release 0.5.0 have been removed from the 0.6.0 release. Following feedback from the PINUG subgroup expert review and escalation to the PSGB and the UK SNOMED CT Edition Committee, the "presence" qualitative interpretation result pattern is under further user research and investigation.

3.3.2 Arbitrary concentration

Where a substance concentration is reported using International Units (IU) or Units (U) then the NPU convention based on IUPAC Silver Book is applied of describing the property as 'arbitrary concentration'. (*ref*). This does not mean the units are arbitrary in the lay sense but that they rely on a designated externally maintained reference as the unit to be measured rather than a mathematic unit. The following pattern can be repeated for any component reported with a Units (U) or International Units (IU) unit of measurement.

Property Attribute | Value Pair

370130000 | Property (attribute) | 118569000 | Arbitrary concentration (property) (qualifier value)

TSH (thyroid stimulating hormone)

FSN: Arbitrary concentration of TSH (thyroid stimulating hormone) in serum

PT: TSH (thyroid stimulating hormone) arbitrary concentration in serum

Autoantibody: Antinuclear Antibody (ANA)

FSN: Arbitrary concentration of antinuclear antibody in serum

PT: Antinuclear antibody arbitrary concentration in serum

Allergen: IgE Antibody to Peanut

FSN: Arbitrary concentration of Arachis hypogaea specific immunoglobulin E in serum

PT: Peanut specific IgE arbitrary concentration in serum

Allergen: IgE Antibody to Peanut Allergen Component

FSN: Arbitrary concentration of recombinant Ara h 2 peanut specific immunoglobulin E antibody in serum

PT: rAra h 2 peanut specific IgE arbitrary concentration in serum

Notes and questions

Could we miss out 'antibody' from terms that already describe an immunoglobulin?

Note that IgE is an approved UK abbreviation and does not require expansion.

Autoantibodies and anti-x antibodies. The policy will follow emerging quality assurance body consensus on descriptions on the use of 'auto-' and 'anti-' prefixes.

'Autoantibody' will not be used, just antibody.

The 'anti-' prefix on substances or organisms will not be supported in terms except in the very few cases of strongest usage. This removes unpredictable variation and makes cataloguing, parsing and searching more reliable.

Specific IgE antibodies: The units used are kU_A/L 'kilounits (A = 'of antibody'?) per litre' (often written without subscript: kUA/L). The property applied is therefore 'arbitrary concentration'.

We acknowledge that 'arbitrary' can get read in its lay sense rather than the purist metrological sense in which it is strictly true. Nevertheless, it is the standard. For end users could we shorten arbitrary concentration in some way? Perhaps 'units concentration'?

3.3.3 Entity count

Although counts have a formal property of 'number/volume' etc this is not expressed directly in terms (although examples are found in SNOMED, including use of American hash '#' for number); instead, the word 'count' is used as a matter of clinical usage.

Example: Neutrophils

Absolute count

FSN: Count of neutrophils in blood

PT: Neutrophil count in blood

Relative count

FSN: Relative count of neutrophils in blood expressed as a percentage (*overworked even if correct?*)

OR

FSN: Percent count of neutrophils in blood

PT: Neutrophil percent count in blood

FSN: Per thousand erythrocytes count of schistocytes in blood by light microscopy

PT: Schistocytes per thousand erythrocytes count in blood by light microscopy

Per thousand is strictly 'per mille' as percent but this seems to not be common usage.

Example: Cluster Of Differentiation (CD)

CD is an approved SNOMED UK abbreviation in the pathology domain (only) and does not require expansion.

Worked example: CD11a

This is shorthand for 'T lymphocyte positive for CD11a antigen'.

FSN Count of T lymphocytes positive for CD11a antigen in blood

PT: CD11a+ count in blood

FSN Count of T lymphocytes positive for CD11a antigen in blood expressed as a percentage

PT: CD11a+ percent count in blood

Notes:

Pre-existing content of long standing may not follow this FSN format nor include 'blood'. However, leucocytes may be counted in other fluids so 'blood' is required here by default.

The specimen is usually blood or bone marrow.

Absolute count means a number per microlitre e.g. $10.0 \times 10^9/L$ and not simply '10,000 cells'. If 'count' is not qualified it is by default an absolute count but 'absolute' is missed out.

Percent count is a count relative to another count. It takes a result of a count and expresses the relative number of cells as a percentage of a higher population level total. Percent, while operating as a UoM in the result is actually only a way of expressing the fraction result but still intrinsic to the description so it is treated as a special case property. This also applies to fractional amounts expressed as a percentage (percent fraction).

3.3.4 Qualitative interpretation of test result for beta review

The representation of qualitative **Presence** terms with associated values of positive/negative/equivocal/etc for a given test result was flagged as a clinical risk by stakeholders and end user experts. Specifically, a risk of default positive interpretation by the clinical recipient if the value on the right is overlooked.

For example, **Presence of HIV 1 RNA by NAAT = negative (value)**

In response to this potential risk, the UTL SNOMED CT representation was integrated into the user research activities in order to ascertain the end user workflow and cognitive process, relative to the current laboratory reporting mechanism and HL7 FHIR design. The examples below summarise the output, but it is **important to note** that the user research output will now be taken through a second stage of engagement to further refine the representation in accordance with user needs. The UTL terminology team has already begun collecting feedback for potential changes from key stakeholders and user experts.

This terminology pattern is therefore still evolving and so is **not included** as versioned SNOMED CT RF2 content in the 0.7.0 RF2 machine readable release.

Instead, the UTL 0.7.0 human readable pack features a separate file containing all the current content in the qualitative interpretation pattern for beta review and feedback. The data will be committed as RF2 machine readable SNOMED CT codes once there is sufficient consensus amongst the expert laboratory and clinical users, and the necessary bulk amendments to the relevant content has been made in agreement with stakeholders.

The updated representation spans all laboratory specialities reporting the outputs of analysers in this format (positive/negative; seen/not seen; isolated/not isolated; detected/not detected etc).

Fully Specified Name - Qualitative interpretation of substance/entity in specimen technique test result (observable entity)

Preferred Term – Substance/entity in specimen qualitative interpretation of technique test result

Microbiology/virology nucleic acid amplification (no specimen):

FSN - Qualitative interpretation of Adenovirus ribonucleic acid nucleic acid amplification test result (observable entity)

PT – Adenovirus RNA qualitative interpretation of nucleic acid amplification test result

Andrology antibody:

FSN - Qualitative interpretation of sperm antibody in sperm immunobead immunoglobulin A test result (observable entity)

PT – Sperm antibody in sperm qualitative interpretation of immunobead immunoglobulin A test result

3.4. Other Worked examples

3.4.1 Enzymes

Enzymes are usually reported by catalytic activity (but sometimes as concentrations) and are constructed as with 'substances' above but with some more specific parameters.

Example: Amylase

246093002 | Component (attribute) | <<90668006 | Enzyme (substance)

370130000 | Property (attribute) | 118523000 | Catalytic activity (property)

FSN: Catalytic activity of amylase in serum

PT: Amylase enzyme activity in serum

Notes

Enzymes can be measured quantitatively but more commonly are reported by catalytic activity. This is expressed as arbitrary concentration. *Is there a case for activity/mass or activity/volume?*

'Enzyme activity' is approved UK terming for enzymes in UTL, rather than 'catalytic activity' or just 'activity'.

3.4.2 Excretion/Output (in urine in 24 hours) (drafting)

Example: Aetiocholanone, 24h, urine

FSN: Mass of aetiocholanone in urine in 24 hours

PT: Aetiocholanone mass in 24 hr urine

Notes

24 hour output/excretion is described with the 24 hour period ascribed to the specimen (24 hour urine)...*add mass/24h, moles/24h property? There is emerging discussion on possibly saying mass/moles and use 'Process duration' attribute for time period.*

Output term needed?
Excretion term needed?

3.4.3 Concentration ratios (draft)

Ratios here are not pure dimensionless ratios but relative concentrations, often of an amount per amount of creatinine. The numerator and denominator of the ratio will therefore need specific substance concentration result codes as a prerequisite.

3.4.2.1 Ratio of two components in one fluid

Albumin/creatinine in urine, mg/mol or mg/mol creatinine

FSN: Mass ratio of albumin to creatinine in urine
PT Albumin/creatinine mass ratio in urine

3.4.2.2 Ratio of a single component in two fluids

Glutamine CSF/plasma, mol/mol

FSN: Substance concentration ratio of glutamine in cerebrospinal fluid and glutamine in plasma
PT Glutamine molar ratio in CSF/plasma

3.4.2.3 Ratio of two components in 24h urine specimen

Calcium/creatinine, urine, 24h, mol/mol

FSN: Substance concentration ratio of calcium to creatinine in 24-hour urine
PT Calcium/creatinine molar ratio in 24h urine

Notes

Ratios can be mass/mass, moles/moles. The albumin example is a mixed mg/mol ratio(?). Is one converted to align units? How is enzyme to non-enzyme managed?

Ratios in 24 hours are described with the 24-hour period ascribed to the urine specimen (24 hour urine). See output/excretion above.

3.4.4 Antimicrobial susceptibility

Attribute: 704320005 | Towards (attribute) |

This attribute is used to define disposition SNOMED CT observable entity concepts in relation to a substance or entity. In the SNOMED CT PaLM extension, this attribute has been used to define microbiology microorganism susceptibility reporting concepts with the following property:

Property: 118588007 | Susceptibility (property) (qualifier value) |

SNOMED CT description pattern example:

FSN: Susceptibility of organism to ampicillin (observable entity)

PT: Organism susceptibility to ampicillin

Where **organism** is postcoordinated and captured as a SNOMED CT (organism) concept, and associated with the susceptibility SNOMED CT (observable entity) code in the information model and messaging specification. This design decision is to prevent an unmanageable quantity of precoordinated SNOMED CT concepts with combinations of organism and antimicrobial substance.

3.5. Further Definition Of Concepts By Assay/Technique/Method Used

Attribute/Value Pair:

246501002 | Technique (attribute)

<<272394005 | Technique (qualifier value)

Although often unstated where assumed or irrelevant, this often has utility in:

- Determining the UoM and thus the property of the UTL member
- Distinguishing between result reference ranges for different assays
- Informing clinical decisions by degree of reliability and significance
- Consistent graphing and trending results over time
- Secondary use in monitoring assay usage over time
- Assisting in short term in migration between an obsolete assay and the latest approved one (but the code itself is then obsolescent).

For these reasons, this attribute is considered definitive in UK UTL terming and classification, alongside the core attribute triad. New concepts may need to be added to allow fuller definition to be attained.

Immunovirology etc content work is under way and the wide range of techniques/methods available will certainly expand as the test method is needed by microbiologists and immunologists

3.6. Relative To

This attribute is used to define the second substance or entity in a ratio report or any result where the value is relative to another value.

4. Molecular Biology - Nucleic Acid Amplification

The procedure codes used historically to record DNA/RNA ‘observable’ reports have generally been termed as ‘[Organism] nucleic acid detection test’. These two different uses have become jumbled. Ontologically this is a detection assay, a test not a test result in SNOMED. SNOMED content in this domain is currently under development and provisionally has been constructed in the following format, subject to editorial approval:

FSN: Presence of human herpesvirus 6 deoxyribonucleic acid in serum by nucleic acid amplification (observable entity)

PT: Human herpesvirus 6 DNA Presence in serum by nucleic acid amplification

Notes

Additional words after ‘amplification’ (e.g. test, method) seem to be redundant.

Content will be further extended merely by replacing ‘nucleic acid amplification’ with the specific method e.g. ‘by RT-PCR’.

Recording organism species/strains not specified in the coded term could be done using a separate ‘type/identity’ code or a text field but this has not been worked through as yet. By this design, the SNOMED CT concept would not precoordinate the specimen as follows:

FSN: Presence of human herpesvirus 6 deoxyribonucleic acid by nucleic acid amplification (observable entity)

PT: Human herpesvirus 6 DNA Presence by nucleic acid amplification

Please note, the sample of microorganism nucleic acid SNOMED CT reporting concepts by presence of RNA/DNA in release 0.5.0 have been removed from the 0.6.0 release and replaced with respective “qualitative interpretation” pattern content for beta review in the UTL 0.7.0 (see section 3.3.4). Following feedback from the PINUG subgroup expert review and escalation to the PSGB and the UK SNOMED CT Edition Committee, the “presence” qualitative interpretation result pattern is under further user research and investigation.

5. Batteries/Profiles/Panels, Screens and Dynamic Function Tests etc.

These coded items do not take a single value but head up a string of single results or an interpretation in text/narrative form (or both). The expectation at this stage is that headings (requests) will be represented by the existing procedure codes which could be handled as a separate set or merged with the UTL set. Where the report is a single result a UTL item can be used here but there may be a case for additional concept additions ending in ‘...interpretation’ on to a test name to support these results. There is a specific field in the developing FHIR message profile for result interpretation. Policy to be developed.

6. Generating Regular SNOMED-Conformant Descriptions From User Requirements

6.1 Thing/Property/System Triad + Technique + Relative To

The data model developer can concatenate elements of terms directly from the parts or derive them from within a template structure via inheritance of term format and modelling. The template could be that used in SNOMED authoring or an independently maintained one aligned with the SNOMED concept model. *Ref SI Templating Guide.*

The heuristic for templating takes the components described above: the thing to be measured, the property of the thing being measured (derived from the report UoM or asserted from research or inherited from supertypes) and the specimen in which the thing is being measured, but also supplemented by the method/technique we are using to take the measurement.

All of the above, as also described, are SNOMED coded and, with access to SNOMED, can be held as lists for concatenation in terms/descriptions in formal SNOMED CT syntax (or in derived intermediate terming standards, mappable to SNOMED because containing the same basic pattern of information). They can also be expanded and improved over time using machine learning and algorithmic refinement.

6.2 Summary of Heuristic Term Formations

Properties:

1. *Amount*
2. *Count*
3. *Fraction or Relative Amount or Count*
4. *Qualitative interpretation Presence/Absence*
5. *Time*
6. *Rate*
7. *Output/Excretion*
8. *Titre*
9. *Activity*
10. *Calculation*
11. *Type, subtype, group, class, grade, phenotype, identity etc.*
12. *Narrative text*

7. Classifying Lab Medicine Observables IN SNOMED

Work In Progress...a set of domains and sub categories to sub-divide the UTL for users.

Appendix 1: Links to Online Resources

Resource	Link
UK Editorial Principles (NHS Digital)	<i>Not currently available</i>
SNOMED International Editorial Principles: ...and specifically on the Observable Entity hierarchy:	https://confluence.ihtsdotools.org/display/DOCEG/SNOMED+CT+Editorial+Guide https://confluence.ihtsdotools.org/display/DOCEG/2.4.5+Observable+Entity
TRUD is NHS Digital's SNOMED CT and Derivative Product Download Site. It can be accessed here:	https://isd.digital.nhs.uk/trud3/user/guest/group/0/home
HL7 FHIR	https://www.hl7.org/fhir/overview.html
NHS Digital UTL page (beta):	https://hscic.kahootz.com/connect.ti/PathologyandDiagnostics/view?objectID=13047024

Appendix 2: Core Attributes and Values Sets

1. Concentrations

Component

246093002 | Component (attribute): <<105590001 | Substance (substance)

Property

370130000 | Property (attribute)

118539007 | Mass concentration (property) (qualifier value)

118556004 | Substance concentration (property) (qualifier value)

118569000 | Arbitrary concentration (property) (qualifier value)

Specimen

704319004 | Inheres in (attribute)

<<309051001 | Body fluid sample (specimen)

e.g.

122575003 | Urine specimen

119361006 | Plasma specimen

119364003 | Serum specimen

258580003 | Whole blood sample

119297000 | Blood specimen

258450006 | Cerebrospinal fluid sample

441620008 | Oral fluid specimen

119339001 | Stool specimen

The default at this point is 309051001 | Body fluid sample (specimen)

Other options for specimen are available.

2. Entity counts

Component

246093002 | Component (attribute) <<410607006 | Organism (organism)

<<123037004 | Body structure (body structure)

Property

370130000 | Property (attribute)

...Number fraction

Specimen

704319004 | Inheres in (attribute)

<<309051001 | Body fluid sample (specimen)

e.g.

122575003 | Urine specimen

119361006 | Plasma specimen

119364003 | Serum specimen

258580003 | Whole blood sample

119297000 | Blood specimen

258450006 | Cerebrospinal fluid sample

441620008 | Oral fluid specimen (forensic use)

119339001 | Stool specimen

Blood spot

The default at this point is 309051001 | Body fluid sample (specimen)

3. Test Method/Technique

246501002 | Technique (attribute)

<<272394005 | Technique (qualifier value)

4. Other Attributes

Quantitative/Qualitative.

This attribute is somewhat redundant to 'property/UoM'? 90% of tests will be quantitative so of questionable value.

Relative to

This is useful to describe second component in relative results like ratios and percentages. It is therefore definitive in SNOMED but the availability to implementers as a useable component has not yet been established.

704325000 | Relative to (attribute) |

<<105590001 | Substance (substance)

<<410607006 | Organism (organism)

<<123037004 | Body structure (body structure)

Appendix 3: Domain-Specific Abbreviation Conventions

The following are approved abbreviations not requiring expansion in UK SNOMED descriptions *in the laboratory medicine domain* (from UK Edition Editorial Principles 2017):

IgA - Immunoglobulin A
IgE – Immunoglobulin E
IgG - Immunoglobulin G
IgM - Immunoglobulin M
CD – Cluster of differentiation
HLA – Human leucocyte antigen

Draft under consideration: CSF, DNA, RNA

National Pathology and Diagnostics

Tel: 0300 30 34 777

E-mail: pathologyanddiagnostics@nhs.net

Internet: <https://digital.nhs.uk/snomed-ct>

IReS (UK Information Representation Services),

NHS Digital,

1 Trevelyan Square,

Boar Lane,

Leeds, LS1 6AE.
